A drug that was developed to treat pancreatic cancer has now been shown to increase symptom-free survival in preclinical medulloblastoma models – all without showing signs of toxicity.
Biosplice searches for a path forward after osteoarthritis drug fails late-stage study
Biosplice’s osteoarthritis drug has failed a Phase 3 clinical trial, according to the drugmaker, significantly clouding the drug’s chances of approval and the future of
April 23, 2024